Cargando…
P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431315/ http://dx.doi.org/10.1097/01.HS9.0000847432.95668.eb |
| _version_ | 1784780020716142592 |
|---|---|
| author | Tivey, A. Shotton, R. Eyre, T. A. Lewis, D. Crosbie, N. Nga, E. Guerrero Camacho, R. Swe, W. Marr, H. Rees, C. Moule, S. Sutton, T. Wrench, D. Thomas, N. Wilson, M. Bailey, J. Prahladan, M. Hodson, A. Koppana, M. Smith, S. Jones, S. Miall, F. Norman, J. Davies, E. Hildyard, C. Lowry, L. Paneesha, S. Qureshi, I. Beech, A. Bedford, C. Everden, A. Tucker, D. Wright, J. Goddard, J. Nicholson, T. Wilson, J. Lord, A. Jackson, B. Flont, M. Gibb, A. Linton, K. |
| author_facet | Tivey, A. Shotton, R. Eyre, T. A. Lewis, D. Crosbie, N. Nga, E. Guerrero Camacho, R. Swe, W. Marr, H. Rees, C. Moule, S. Sutton, T. Wrench, D. Thomas, N. Wilson, M. Bailey, J. Prahladan, M. Hodson, A. Koppana, M. Smith, S. Jones, S. Miall, F. Norman, J. Davies, E. Hildyard, C. Lowry, L. Paneesha, S. Qureshi, I. Beech, A. Bedford, C. Everden, A. Tucker, D. Wright, J. Goddard, J. Nicholson, T. Wilson, J. Lord, A. Jackson, B. Flont, M. Gibb, A. Linton, K. |
| author_sort | Tivey, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431315 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94313152022-08-31 P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY Tivey, A. Shotton, R. Eyre, T. A. Lewis, D. Crosbie, N. Nga, E. Guerrero Camacho, R. Swe, W. Marr, H. Rees, C. Moule, S. Sutton, T. Wrench, D. Thomas, N. Wilson, M. Bailey, J. Prahladan, M. Hodson, A. Koppana, M. Smith, S. Jones, S. Miall, F. Norman, J. Davies, E. Hildyard, C. Lowry, L. Paneesha, S. Qureshi, I. Beech, A. Bedford, C. Everden, A. Tucker, D. Wright, J. Goddard, J. Nicholson, T. Wilson, J. Lord, A. Jackson, B. Flont, M. Gibb, A. Linton, K. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431315/ http://dx.doi.org/10.1097/01.HS9.0000847432.95668.eb Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Tivey, A. Shotton, R. Eyre, T. A. Lewis, D. Crosbie, N. Nga, E. Guerrero Camacho, R. Swe, W. Marr, H. Rees, C. Moule, S. Sutton, T. Wrench, D. Thomas, N. Wilson, M. Bailey, J. Prahladan, M. Hodson, A. Koppana, M. Smith, S. Jones, S. Miall, F. Norman, J. Davies, E. Hildyard, C. Lowry, L. Paneesha, S. Qureshi, I. Beech, A. Bedford, C. Everden, A. Tucker, D. Wright, J. Goddard, J. Nicholson, T. Wilson, J. Lord, A. Jackson, B. Flont, M. Gibb, A. Linton, K. P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_full | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_fullStr | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_full_unstemmed | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_short | P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY |
| title_sort | p1141: ibrutinib and rituximab as first line therapy for mantle cell lymphoma: a multicentre, real-world uk study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431315/ http://dx.doi.org/10.1097/01.HS9.0000847432.95668.eb |
| work_keys_str_mv | AT tiveya p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT shottonr p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT eyreta p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT lewisd p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT crosbien p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT ngae p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT guerrerocamachor p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT swew p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT marrh p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT reesc p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT moules p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT suttont p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT wrenchd p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT thomasn p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT wilsonm p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT baileyj p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT prahladanm p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT hodsona p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT koppanam p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT smiths p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT joness p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT miallf p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT normanj p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT daviese p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT hildyardc p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT lowryl p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT paneeshas p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT qureshii p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT beecha p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT bedfordc p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT everdena p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT tuckerd p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT wrightj p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT goddardj p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT nicholsont p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT wilsonj p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT lorda p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT jacksonb p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT flontm p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT gibba p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy AT lintonk p1141ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaamulticentrerealworldukstudy |